NSE ScannerPharmaceuticals · Biotechnology · NSE: HALEOSLABS · data 2026-10-30
Haleos Labs Ltd.
In plain words
Price: 21.4% below its 52-week high of ₹1,774.
Delivery: 82.7% of traded shares were kept for delivery over the last 10 sessions, against 79.8% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Jun 2026 (-36.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹324 cr |
| Net profit (last 12 months) | ₹16 cr |
| Sales growth, 3 years (yearly) | 1.9% |
| Profit growth, 3 years (yearly) | 14.7% |
Latest results in brief (Q1 FY27)
HALEOSLABS Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹72.94 crore, down 11.6% YoY and down 2.9% QoQ.
Net profit was ₹2.65 crore, down 36.3% YoY and up 502.3% QoQ.
Operating margin was 12.5% (14.2% a year ago).
EPS was ₹8.75, down 36.4% YoY and up 507.6% QoQ.
HALEOSLABS के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹72.94 करोड़; पिछले साल की तुलना में 11.6% की गिरावट, पिछली तिमाही की तुलना में 2.9% की गिरावट।
शुद्ध मुनाफ़ा: ₹2.65 करोड़; पिछले साल की तुलना में 36.3% की गिरावट, पिछली तिमाही की तुलना में 502.3% की बढ़त।
ऑपरेटिंग मार्जिन: 12.5% (एक साल पहले 14.2%)।
EPS: ₹8.75; पिछले साल की तुलना में 36.4% की गिरावट, पिछली तिमाही की तुलना में 507.6% की बढ़त।
HALEOSLABSના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹72.94 કરોડ; ગયા વર્ષની સરખામણીએ 11.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 2.9% ઘટાડો.
ચોખ્ખો નફો: ₹2.65 કરોડ; ગયા વર્ષની સરખામણીએ 36.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 502.3% વધારો.
ઓપરેટિંગ માર્જિન: 12.5% (એક વર્ષ પહેલાં 14.2%).
EPS: ₹8.75; ગયા વર્ષની સરખામણીએ 36.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 507.6% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 12/30: Delivery 84.2% over the last 20 sessions vs 82.3% in the 40 before (1.02x); shares delivered per day 1.39x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 23 Sept 26Dividend Dividend ₹1.5 (ex-date) +0.2% next session
- 5 Aug 26Results Q1 FY27 results: profit −36.3% YoY -6.6% next session
- 29 May 26Results Q4 FY26 results: profit −85.2% YoY -12.8% next session
- 11 Feb 26Results Q3 FY26 results: profit +21.0% YoY -1.4% next session
- 10 Nov 25Results Q2 FY26 results: profit +30.6% YoY +5.7% next session
- 24 Sept 25Dividend Dividend ₹1.5 (ex-date) +0.6% next session
- 11 Aug 25Results Q1 FY26 results: profit −40.6% YoY -3.0% next session
- 29 May 25Results Q4 FY25 results: profit −49.7% YoY -2.2% next session
- 12 Feb 25Results Q3 FY25 results: profit +27.2% YoY +6.1% next session
- 14 Nov 24Results Q2 FY25 results: profit +597.0% YoY -9.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹73 cr | ₹3 cr | -36.3% | 12.5% | 8.75 |
| Mar 2026 | ₹75 cr | ₹0 cr | -85.2% | 5.5% | 1.44 |
| Dec 2025 | ₹95 cr | ₹7 cr | +21.0% | 14.8% | 21.89 |
| Sept 2025 | ₹81 cr | ₹6 cr | +30.6% | 16.7% | 20.19 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 72.11% | 72.11% | 72.11% | 71.80% |
| Foreign institutions (FII) | — | — | — | — |
| Domestic institutions (DII) | 0.31% | 0.31% | 0.30% | 0.29% |
| Mutual funds | — | — | — | — |
| Retail investors | 21.43% | 21.32% | 21.66% | 22.15% |
| Number of shareholders | 6,765 | 6,859 | 6,937 | 7,125 |
Common questions
What was Haleos Labs Ltd.'s latest quarterly profit?
Haleos Labs Ltd. reported a net profit of ₹3 cr for the quarter ended Jun 2026 (-36.3% on the same quarter a year earlier), on revenue of ₹73 cr.
How much do promoters hold in Haleos Labs Ltd.?
Promoters held 72.11% of Haleos Labs Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Haleos Labs Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.52.
What is Haleos Labs Ltd.'s P/E ratio?
About 26.7, based on the last 12 months' earnings and a price of ₹1,394.4 (data 2026-10-30).
What is the 52-week high and low of Haleos Labs Ltd.?
The 52-week high is ₹1,774 and the 52-week low is ₹1,091.1.
Similar companies
Anthem Biosciences Limited (ANTHEM) · Rubicon Research Limited (RUBICON) · Akums Drugs and Pharmaceuticals Limited (AKUMS) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open HALEOSLABS in NSE Scanner →